BR9713388A - Processos de produção de vìrus e de adenovìrus recombinantes defectivos, baculovìrus recombinante, e, preparação viral purificada - Google Patents

Processos de produção de vìrus e de adenovìrus recombinantes defectivos, baculovìrus recombinante, e, preparação viral purificada

Info

Publication number
BR9713388A
BR9713388A BR9713388A BR9713388A BR9713388A BR 9713388 A BR9713388 A BR 9713388A BR 9713388 A BR9713388 A BR 9713388A BR 9713388 A BR9713388 A BR 9713388A BR 9713388 A BR9713388 A BR 9713388A
Authority
BR
Brazil
Prior art keywords
adenoviruses
production processes
recombinant
purified viral
viral preparation
Prior art date
Application number
BR9713388A
Other languages
English (en)
Other versions
BR9713388B1 (pt
Inventor
Hel Ne Leblois-Prehaud
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Original Assignee
Rh Ne Poulenc Rorer S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9497899&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9713388(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rh Ne Poulenc Rorer S A filed Critical Rh Ne Poulenc Rorer S A
Publication of BR9713388A publication Critical patent/BR9713388A/pt
Publication of BR9713388B1 publication Critical patent/BR9713388B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pens And Brushes (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

-se a um processo para produzir vírus recombinante. Este processo é baseado no uso de baculovírus pa refere a construções usadas para implementar este processo, a produção de células, e o vírus resultante.
BRPI9713388-4A 1996-11-22 1997-11-18 processos de produÇço de vÍrus e de adenovÍrus recombinantes defectivos, e baculovÍrus recombinante. BR9713388B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9614278A FR2756297B1 (fr) 1996-11-22 1996-11-22 Procede de production de virus recombinants
PCT/FR1997/002073 WO1998022607A1 (fr) 1996-11-22 1997-11-18 Procede de production de virus recombinants

Publications (2)

Publication Number Publication Date
BR9713388A true BR9713388A (pt) 2000-03-21
BR9713388B1 BR9713388B1 (pt) 2009-01-13

Family

ID=9497899

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713388-4A BR9713388B1 (pt) 1996-11-22 1997-11-18 processos de produÇço de vÍrus e de adenovÍrus recombinantes defectivos, e baculovÍrus recombinante.

Country Status (18)

Country Link
US (2) US6387670B1 (pt)
EP (1) EP0946741B1 (pt)
JP (1) JP4686670B2 (pt)
KR (1) KR100719645B1 (pt)
AT (1) ATE317908T1 (pt)
AU (1) AU731106B2 (pt)
BR (1) BR9713388B1 (pt)
CA (1) CA2271438C (pt)
CZ (1) CZ293947B6 (pt)
DE (1) DE69735274T2 (pt)
ES (1) ES2260803T3 (pt)
FR (1) FR2756297B1 (pt)
HU (1) HU224713B1 (pt)
IL (1) IL129686A (pt)
NO (2) NO323937B1 (pt)
SK (1) SK286900B6 (pt)
WO (1) WO1998022607A1 (pt)
ZA (1) ZA9710516B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2375119A1 (en) * 1999-05-27 2000-12-07 Genovo, Incorporated Compositions and methods for production of recombinant virus using a carrier vector derived from a nonmammalian virus
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
AU5448400A (en) * 1999-05-28 2000-12-18 Mount Sinai School Of Medicine, The A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
GB9919409D0 (en) 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
JP2006515162A (ja) 2002-08-29 2006-05-25 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 環状核酸ベクター、ならびに同ベクターの作製法および使用法
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
GB0702694D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Vectors
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2249950B1 (en) * 2008-03-05 2014-10-15 Council of Scientific & Industrial Research A polymeric hybrid membrane
EP2287323A1 (en) 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
EP2292781A1 (en) 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
CN102884196B (zh) * 2010-04-01 2015-05-06 肖卫东 重组病毒载体的结构及其制备
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
US9677088B2 (en) 2012-05-09 2017-06-13 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
CA2877428A1 (en) 2012-06-21 2013-12-27 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
EP3039129B1 (en) * 2013-08-30 2018-06-27 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
AU2015231439B2 (en) 2014-03-17 2019-11-14 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
KR20170137730A (ko) 2015-03-02 2017-12-13 애드베룸 바이오테크놀로지스, 인코포레이티드 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
JP2021503960A (ja) 2017-11-27 2021-02-15 コーダ バイオセラピューティクス， インコーポレイテッド 神経疾患のための組成物および方法
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
WO2019161365A1 (en) 2018-02-19 2019-08-22 Homology Medicines, Inc. Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
WO2020160508A1 (en) 2019-01-31 2020-08-06 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids
WO2021035179A1 (en) 2019-08-21 2021-02-25 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
WO2023212298A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Bispecific antibodies and methods of treating ocular disease
WO2023212294A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Angiopoietin-related protein 7-specific antibodies and uses thereof
WO2023212293A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Complement factor h related 4-specific antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441897A4 (en) * 1988-11-14 1992-06-24 Us Health Parvovirus capsids
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
AU702830B2 (en) * 1994-09-23 1999-03-04 General Hospital Corporation, The Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell

Also Published As

Publication number Publication date
IL129686A0 (en) 2000-02-29
CZ182299A3 (cs) 1999-08-11
IL129686A (en) 2005-12-18
HUP0001762A2 (hu) 2000-09-28
KR20000057202A (ko) 2000-09-15
SK286900B6 (sk) 2009-07-06
AU5226198A (en) 1998-06-10
KR100719645B1 (ko) 2007-05-17
ATE317908T1 (de) 2006-03-15
CZ293947B6 (cs) 2004-08-18
FR2756297B1 (fr) 1999-01-08
HU224713B1 (en) 2006-01-30
FR2756297A1 (fr) 1998-05-29
US6387670B1 (en) 2002-05-14
SK66699A3 (en) 2000-02-14
CA2271438A1 (fr) 1998-05-28
NO992464D0 (no) 1999-05-21
NO2013009I1 (no) 2013-04-29
NO992464L (no) 1999-06-23
DE69735274T2 (de) 2006-10-12
JP4686670B2 (ja) 2011-05-25
NO323937B1 (no) 2007-07-23
AU731106B2 (en) 2001-03-22
HUP0001762A3 (en) 2002-01-28
ES2260803T3 (es) 2006-11-01
JP2001503993A (ja) 2001-03-27
WO1998022607A1 (fr) 1998-05-28
BR9713388B1 (pt) 2009-01-13
CA2271438C (fr) 2010-10-26
DE69735274D1 (de) 2006-04-20
EP0946741B1 (fr) 2006-02-15
ZA9710516B (en) 1998-06-10
EP0946741A1 (fr) 1999-10-06
US20030022356A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
BR9713388A (pt) Processos de produção de vìrus e de adenovìrus recombinantes defectivos, baculovìrus recombinante, e, preparação viral purificada
BR0016390A (pt) Componente piezelétrico
ATE353017T1 (de) Herstellung von impstoffen zür vorbeugung von pathogenen zuständen einer hiv retroviraler infektion
BR9006422A (pt) Processo para preparar um polipeptidio viral pt-nanbh e processo para detectar o mesmo
BR9710030A (pt) Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]
ATE236262T1 (de) Rekombinanter schweinepocken-virus
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
CA2072573A1 (en) Treatment of human retroviral infections with 2',3'-dideoxyinosine
CL2004000031A1 (es) Compuestos derivados de n-arilamidas de acidos sulfonilamino carboxilicos sustituidos con azufre; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para tratar la hipertension, angina de pecho, restenosis, infarto al miocard
CA2258217A1 (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
DE3853422D1 (de) HIV-3-Retrovirus und seine Verwendung.
PT102022A (pt) Processo para a producao e purificacao de astaloglicoprotetinas adequadas para uso em vacinas e conjunto de materiais de ensaio para detectar a sua presenca
ES2078255T3 (es) Regiones inmunogenas en la proteina e-7 del papilomavirus humano tipo 16.
BR9910990B1 (pt) processo para a preparaÇço de uma dextrina de amido, dextrina de amido, adesivo, papel, e, uso de uma dextrina de amido.
ES2121714T1 (es) Herramienta de corte ceramica reforzada con filamentos, y su composicion.
BR9007965A (pt) Estruturas laminadas contendo adesivo,polimeros grafitizados aqueciveis por rf e misturas
ATE164853T1 (de) Peptide, von virus-hiv-hüllen-glycoproteinen abstammend, deren verwendung zum nachweis einer infektion dieser viren und für die impfung gegen aids
DE68910008D1 (de) Polymetallosilazane, verwendbar zur Herstellung von keramischen Fibern auf der Basis von Siliziumnitrid.
CA2015608A1 (en) Alumina-titanium carbide-silicon carbide composition
ES2078971T3 (es) Produccion de virus y purificacion de proteinas con envoltura virica para uso en vacunas.
BR9913649A (pt) Rede anelar wdm
DE69021625D1 (de) Breitband-Koppelfeld mit deaktivierten Koppelpunkten zur Herstellung von Vermittlungswegen.
HUP9800113A2 (hu) Transzgenikus vírus
DK0885013T3 (da) Anvendelse af multipotente paramunitetsinducere fra svækkede, ikke-immunogene poxvirus eller parapoxvirus til fremstilling af lægemidler
AU6551800A (en) Dinucleoside 5',5'-tetraphosphates as inhibitors of viral reverse transcriptasesand viruses

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25A Requested transfer of rights approved

Free format text: GENCELL S.A. (FR)

B25D Requested change of name of applicant approved

Owner name: GENCELL SAS (FR)

Free format text: ALTERADO DE: GENCELL S.A.

B25D Requested change of name of applicant approved

Owner name: CENTELION (FR)

Free format text: ALTERADO DE: GENCELL SAS

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2009, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 10.03.2019